We observed significant (p < 0.0001, Fishers exact test) mutual exclusivity between ESR1 and TP53 mutations (Fig. 1b) with co-occurrence of mutation in only 25 breast cancers out of 1056 examined. This evidence concerns the gene ESR1 and breast carcinoma.